1. Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma
   Maximiliano Servin-Rojas et al, 2024, Surgery CrossRef
2. Massive ovarian edema with paraovarian cyst torsion treated with laparoscopic surgery: A case report
   Takeshi Fukuda et al, 2021, Medicine International CrossRef
3. Low Carbohydrate Antigen 19-9 (CA 19-9) Levels in a Patient Highly Suspected of Having Caput Pancreas Tumor
   Bernard Jonathan Christian Yong et al, 2022, Cureus CrossRef
4. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity
   Sam Z. Thalji et al, 2023, Journal of Surgical Oncology CrossRef
5. Isolation of exosomes from whole blood by a new microfluidic device: proof of concept application in the diagnosis and monitoring of pancreatic cancer
   María Sancho-Albero et al, 2020, Journal of Nanobiotechnology CrossRef
6. Electrochemical immunoplatform to help managing pancreatic cancer
   Víctor Pérez-Ginés et al, 2023, Journal of Electroanalytical Chemistry CrossRef
7. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer
   Sam Z. Thalji et al, 2023, Annals of Surgical Oncology CrossRef
8. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
   Guopei Luo et al, 2021, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
9. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer
   Andrii Khomiak et al, 2020, Cancers CrossRef